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Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trial
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BARRY S, GEORGE, MD§
Ann Arbor. Michigan, Durham, North Carolina and Cincinnati and Columbus. Ohio
The Thrombolysis and Angioplasty in Myocardial In-
farction (TAMI) trial was a randomized, multicenter
study performed to determine whether immediate or
elective (7 day) coronary angioplasty was preferable once
infarct vessel recanalization had been confirmed. In ad-
dition, a major focus ofthe effort was to collect detailed
information about the clinical course and outcome of all
386 patients entered into the trial, whether randomized
or not.
This article reports the major end points of acute and
follow-up mortality, the incidence and timing of recur-
Rationale of the Trial
Randomized controlled trials of early intravenous throm-
bolytic therapy for acute myocardial infarction (1-4) have
demonstrated the salutary effects of decreased mortality,
improved left ventricular function and limitation of infarct
size. These studies have employed high dose intravenous
streptokinase. The Thrombolysis in Myocardial Infarction
(TIMI) (5) and European Cooperative Study Group Trials
(6) directly comparing streptokinase and recombinant tissue-
type plasminogen activator (rt-PA) have demonstrated that
rt-PA has superior coronary thrombolytic efficacy. On the
basis of published major results of early fibrinolytic therapy
for myocardial infarction (1-8), one may conclude that such
intervention is safe, effective and vital in selected patients.
As experience continues to accrue, early intravenous fibri-
nolytic therapy has become standard care for certain patients
with acute myocardial infarction.
After reperfusion induced by thrombolytic therapy, the
majority of patients are left with a significant infarct-related
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rent ischemic events and acute and convalescent infarct-
vessel patency, The optimal timing of coronary angio-
plasty and intravenous tissue plasminogen activator (rt-
PMadministration is discussed. The subsets of patients
who: I) were unsuccessfully treated with rt-Pa; 2) had
a minimal residual «SO%) lesion after rt-PA j or 3)
underwent emergency' coronary bypass surgery' are pre-
sented. A current practical approach to acute interven-
tion is extrapolated from the TAMI results.
(J Am Coli Cardiol 1987;10:658-748)
coronary artery stenosis, as detected by angiography (9,10),
This finding led Meyer et al.. (II) in 1982 to combine
intracoronary fibrinolytic therapy with acute coronary an-
gioplasty. Later, O'Neill and colleagues (12) showed that
coronary angioplasty, compared with intracoronary strep-
tokinase therapy. achieved more significant reduction in the
residual infarct vessel stenosis and suggested that coronary
angioplasty promotes more recovery of regional and global
ventricular function. Pilot studies of intravenous rt-PA and
coronary angioplasty (13,14) further raised the issue of the
importance of mechanical intervention for improvement of
ventricular function.
Thus, the integration of intravenous rt-PA with coronary
angioplasty appeared to be promising, but the role and proper
timing of angioplasty after successful coronary thrombolysis
remained unclear. The chief purpose of the Thrombolysis
and Angioplasty in Acute Myocardial Infarction (TAMI)
trial, was to determine whether immediate or deferred (7
day) angioplasty was preferable once myocardial reperfu-
sion had been confirmed.
Additionally, because previous trials of thrombolysis have
concentrated on major end points such as mortality and left
ventricular function, many important details about the clin-
icalcourse of patients with acute myocardial infarction treated
with an aggressive strategy of revascularization are not
available. For this reason. a major focus of our efforts was
to collect detailed information about the clinical course and
outcome of all patients entered into the trial, whether ran-
domized or not. Thus, the entire TAMI trial can be viewed
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as a specific randomized trial within a larger clinical data
base designed to provide insight into multiple clinical issues.
PTCA Random ize
A{..--' ---------""'1
Figure I. The Thrombolysis and Angioplasty in Myocardial In-
farction (TAM)) protocol. Cath :=0 cardiac catheterization: IV t-
PA = intravenous tissue-type plasminogen activator ( 150 mg over
6 to ~ hours): MI = myocardial infa rction; PTCA = percutaneous
transluminal coronary angioplasty,
Study Design
The entry criteria included: I) age -:::; 75 years; 2) chest
discomfort for > 20 minutes and < 4 hours. unrelieved by
nitroglycerin: or severe, ongoing chest pain -:::; 6 hours in
duration; 3) > I mm of ST segment elevation in two con-
tiguous electrocardiographic (ECG) leads; 4) no bleeding
predisposition. recent trauma, stroke or surgery; 5) no prior
coronary artery bypass graft surgery or previous myocardial
infarction in the same territory; and 6) absence of cardio-
genic shock as defined by systolic blood pressure below 85
mm Hg unresponsive to volume expansion.
Protocol algorithm (Fig. I). The dose of rt-PA was a
total of 150 mg over 6 to 8 hours. with the first hour dose
given as 60 mg for the fi rst 178 patients and 1.0 mg/kg
body weight for the remaining 208 patients (10% as a bolus).
All patients underwent coronary and left ventricular angi-
ography at 90 minutes after initiation of intravenous rt-PA.
On the basis of the final 90 minute coronary angiogram (not
more than four selective contrast injections). triage to one
of three groups was made.
In Group I, the infarct vessel remained completely oc-
cluded 90 minutes after lytic therapy. At the discretion of
the investigator coronary angioplasty could he performed to
achieve recanalization. III Group II, the infarct vessel was
patent. defi ned as TIMI grade 2 or 3 fl ow (5). there was a
significant ( :2:50% luminal diameter) residual stenosis and
the lesion was suitable for balloon dilation. In Group III,
the infarct vessel was recanalized but one of the following
conditions. precluding randomization to coronary angie-
plasty. was present: left main coronary or equivalent stenosis
(22%); diffuse. severe. multilesion or rnultivessel coronary
disease (39%); an unidentifiable infarct vessel due to am-
biguity of the ECG-angiographic correlation (3%); cardio-
genic shock (4%); only a minimal « 50%) residual lesion
(25%) : or miscellaneous exclusions (7 % ).
Immediately after triage , Group II patients were random-
ized to either immediate coronary angioplasty or deferred
angioplasty at 7 days if clinically indicated. All patients
received concomitant heparin, aspirin and dipyridamole,
and diltiazem therapy. Beta-receptor blocker agents were
not administered unless specifi cally indicated to treat hy-
pertension, recurrent angina or supraventricular tachycardia.
Repeat angiography was performed 7 to 10 days after ad-
mission for determination of infarct vessel patency status
and convalescent ventricular function.
End Points and Analysis
Left ventricular function. Because of the extremely
large sample size required for other end points. the major
end point for the trial was lert ventricular function. which
served as the basis for sample size calculation. Using the
area-length and centerline chord methods, global ejection
fraction and infarct regional wall motion. respectively (15).
were determined at the angiographic core laboratory, with-
out knowledge of patient identity and therapy. Paired ven-
triculograms (immediate and 7 day) were obtained in 183
(95%) of 193 randomized patients who survived the hos-
pitalization. The ventriculographic studies were technically
adequate in 148 (75o/c) of 198 randomized patients. Ven-
tricular function was similarly studied in patients who did
not meet criteria for randomization.
Infarct vessel patency. The second end point was infarct
vessel patency status at 90 minutes after rt-PA therapy and
at 1 week. If the patient underwent coronary artery bypass
surgery during this time interval. repeat angiography was
performed before hospital discharge to define the graft and
native vessel patency status to the infarct zone. as weft as
ventricular function. Similarly. when patients required an
emergency coronary angiogram or angioplasty or both. be-
fore day 7. a third cardiac catheterization done before hos-
pital discharge provided the follow-up vessel patency data.
These studies were reviewed at the core angiographic facility
for final determination of patency status.
Clinical outcomes. The third set of end points for the
trial were the clinical outcomes: mortality, recurrent isch-
emia, need for an emergency revascularization procedure
and reocclusion. Acute mo rtality was delined as any death
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'Total ill each group represents the number of patients who survived
the hospitalization Abbreviations as in Tahle I.
Table 2. Coronary Artery Bypass Graft Surgery (CABG) in 77
TAMI Patients Before Hospital Discharge
therapy was not successful, acute infarct vessel patency was
achieved in 363 patients (94 c/c,) .
Predischarge vessel patency. At follow-up angiogra-
phy. 246 (69o/c) of 359 surviving patients had a patent in-
farct-related artery after medical therapy or coronary an-
gioplasty. Of these 246 patients. 193 (78%) had :::::50?e
residual stenosis and 53 (22%) had >50% stenosis. A bypass
graft to the infarct territory was present in 77 (21rYe) of the
359 patients and graft patency was angiographically docu-
mented in 66 (86%) of 77 patients of this group. In Table 2,
the proportion of surviving patients in each group who
underwent surgical coronary recanalization before hospital
discharge is presented. An occluded infarct vessel without
a bypass graft was present at discharge in 36 patients (10%).
Thus. 323 (90%) of 359 patients were discharged from the
hospital with a patent coronary artery or bypass graft sup-
plying the infarct territory.
before hospital discharge, regardless of the length of the
hospitalization. Emergencycoronary artery bypass grafting
was recorded only if the patient went directly to surgery
from the cardiac catheterization laboratory. All other coro-
nary bypass procedures occurring before 7 days or rollow-
up were defined as .'urgent. ,. Recurrent ischemia was re-
corded as a clinical end point when the patient experienced
protracted C~20 minutes) chest discomfort associated with
ECG changes, whether or not the infarct vessel had reoc-
eluded The need for emergency coronary artery bypass
surgery or angioplasty during the hospital course was de-
termined after coronary angiography when a recurrent isch-
emic episode occurred, as defined previously. Reocclusion
was defined as closure of the infarct vessel on repeal coro-
nary angiography after the patient had left the cardiac cath-
eterization laboratory from the initial procedure.
Technical success or failure of the coronary anglo'
plasty. This constituted a fourth end point. COm,)I('/(' an-
giogranhic success meant that :::::50% residual diameter ste-
nosis had been achieved with preserved flow at the completion
of the procedure (TIMI grade 2 or 3) (5). Partial success
denoted preserved flow but a residual narrowing of >5(YIt-"
Failure was defined as closure of the infarct-related artery
after coronary angioplasty. with or without the need for
emergency surgical revascularization. Patients with flow
maintained by a transluminal reperfusion catheter were con-
sidered to have coronary angioplasty failure (16). A more
in depth discussion of methods and end points in the trial
is provided in the primary report (17).
Group of Patients
Unsuccessful rt-PA
Randomized
Immediate angioplasty
Deferred anglOplasty
Nonrandomized
T(ltal
No CABG/Total"
IO/X6
14/95
15/97
.lX/XI
77:359
(Ir
12
I:>
I (J
47
21
Table 1. Infarct Vessel Patency in 386 Patients
Acute = 90 minutes after rt-FA therapy: JMA = internal mammary
artery fran: iv = intravenous: n-PA = tissue-type plasminogen activator:
SVO = saphenous vein gralt
Results of Therapy
Infarct Vessel Patency
Patency at 90 minutes. Coronary angiographie results
90 minutes after rt~PA infusion for the 386 patients enrolled
are summarized in Table 1. Overall. 288 patients (75%)
demonstrated patency at 90 minutes. With successful emer-
gency coronary angioplasty in 71 patients in whom rt-PA
No. of Patients C;(
Follmv-lJp Mortality
Survival status at 6 months has been determined by clinic
follow-up, telephone or mail for 357 (99.4%) of the 359
patients who survived the initial hospitalization. There have
Acute Mortality
The overall in-hospital mortality rate in the trial was 27
(7.0%) of 386 patients. A patent infarct vessel on the initial
angiogram was associated with a lower mortality rate: patent
15 (5.2S·n of 288: occluded LO (I0Ao/c) of 96, P = 0.05.
The 10.49(. mortality rate in the group unsuccessfully treated
with rt~PA oceurn:d despite attempted coronary angioplasty
in the majority (S6 190% 1of 96) of these patients. Patients
with a patent vessel in the nonrandomized group. which
mostly comprised high risk coronary anatomic subsets, also
had a significantly increased mortality compared with those
with an infarct vessel suitable for angioplasty randomization
(II % versus 2.5 cl., p < O,OO\). As shown in Table 3,
variables associated with increased in-hospital mortality in-
clude: advanced age, female gender, compromised baseline
left ventricular function. failure of rt-PA-mediated reca-
nalization, failed angioplasty and reocclusion.
75
94
69
54
15
21
10
246
193
53
77
36
2XX
361
Acute (n = 3X6)
iv rt-PA
iv rt-PA and coronary angioplasty
Predischarge (n = 35t)}
Infarct vessel patency
$50% Stenosis
>:>0";;, Stenosis
Bypass graft (IYlA or SVG)
Occluded
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Variable
Age (yr)
Female ('7<:)
Failure of t-PA rcpcrfusion ('7<:)
Failure or angioplasty ( ',i )
Acute EF (mean 2: SDj
Reocclusiou (o/c)
Died
(n = 27)
61.9 -'- ~u;
33
40
47
0.45 ± 0.14
30
Survived
(n - 359 )
55.5 ± 10.5
21
24
17
0.52 ± 0.11
14
p Value
0 .0015
O.I3
0.08
n.005
0.02
0.03
EF = ejection fraction; other abbreviations as in Table I.
been only fi ve deaths (1.4% mortality rate). One patient
died suddenly with underlying coronary anatomy of a 30%
lesion at 90 minutes after rt-PA and at I week follow-up.
Clinically, it was believed that this patient suffered from
coronary artery spasm. Two other patients had out-of-hos-
pital sudden death; one of these occurred 6 months after
three vessel coronary bypass surgery. The remaining two
deaths were of noncardiac origin, one due to malignancy
and a seconddue to hepatic failure from alcoholic cirrhosis.
Timing of Coronary Angioplasty
Strategies for timing (Table 4). Two strategiesof coro-
nary angioplasty timing were compared using data from the
trial. Technical success rates were high for both immediate
and deferred coronary angioplasty, with an insignificant trend
toward higher success with the latter approach (90% versus
94%, respectively, p = NS). Only half(51%) of the patients
randomized to deferred angioplastyeventually had the pro-
cedure, a reflection of several important factors . First, in
nearly 15% of these patients. a significant residual stenosis
was no longer present at follow-up coronary angiography,
probably because of continued clot lysis. Second, another
13% of patients preferentially underwent surgical revascu-
Table 4. Timing of Coronary Angioplasty
Immediate Angioplasty
High success rate (>90%)
Low reocclusion rate (11%)
Infarct zone wall motion improvement
Preservation of global ejection fraction
High rate of emergency CABO (7%j
Low rate of elective CABO (4%)
Low recurrent ischemia, repeat emergency
angioplasty rate (5%)
Permits angioplasty recanalization of patients
with failure of rt-PA and high overall
patency of infarct-related artery (94'7~j
May unnecessarily approach patients who
would not have a critical stenosis at restudy
Requires 24 hour on-call team, regional center
and rapid interhospital transport system
larization, either because of the complexity of the infarct
vessel lesion or the presence of significant multiple vessel
disease. Third. 20%of patientsrandomized to deferredcoro-
nary angioplasty were discharged from the hospital with
medical therapy. Of these 20 patients, II had a negative
submaximal exercise test before the repeat catheterization;
4 were found to have reocclusion at follow-up catheteriza-
tion and. by design, angioplasty of a total occlusion at 7
days was not performed: 2 were deferred for angiographic
study until I to 2 weeks after hospital discharge because of
logistic scheduling difficulties; and 3 refused repeat cathe-
terization and mechanical or surgical revascularization .
Emergency bypass surgery was required more frequently
in patients undergoing immediate versus deferred angio-
plasty (7% versus 2%, respectively) but this difference was
not statistically significant. Similarly, the in-hospital mor-
tality rate was not significantly different between the two
strategies (4% versus I%, respectively).
Effects on ventricular function. Both strategies dem-
onstrated remarkably similareffects on ventricular function .
Both immediate and deferred angioplasty were associated
with improvement of infarct zone regional wall motion and
preservation of, without significant improvementof, global
function . Importantly, 80 (82%) of the patients randomized
Deferred Angioplasty
High success rate (> 90%)
Low reocclusion rate ( 13'k)
Infarct zone wall motion improvement
Preservation of global ejection fraction
Low rate of emergency CABO (2%)
Higher rate of elective CABO ( 100/,)
High recurrent ischemia and emergency
angioplastylCABO rate ( 19Ck)
Overall patency of infarct-related artery only related
to chemical and spontaneous reperfusion
Allows time for more complete thrombolysis
leading to an insignificant residual stenosis (14%)
Requires 24 hour on-call team. regional center if
recurrent ischemia is treated
Numbers in parentheses correspond to TAMI data. Abbreviations as in Tables I and 2.
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Figure 2. Timing of recurrent ischemic events and reocclusion
after successful recombinant tissue-type plasminogen activator (t-
PAl-mediated thrombolysis. Number of events (reocclusion and
ischemia) are plotted for the Yl; patients randomized to deferred
(7day)coronaryangioplasty (PTCA) . Hatchedbars indicatereoc-
elusion: open bars indicate ischemic crossover. Rx = therapy.
to delayed angioplasty had not undergone mechanical or
surgical revascularization at the time follow-up ventricu-
lographic data were acquired. Because deferred angioplasty
was done subsequent to the 7 day left ventriculogram. the
comparison groups for the effects of ventricular function
were actually rt-PA and immediate angioplasty versus rt-
PA alone. Further. when the 18patients who had angioplasty
or bypass surgery before repeat catheterization were elim-
inated from the analysis, the same extent of regional wall
motion improvement was demonstrated in the remaining
patients. Thus. with successful recanalization at t-PA. there
was significant potentiation of regional infarct zone function
within I week. without the requirement for immediate an-
gioplasty.
Limitations of deferred angioplasty. The major short-
coming of the deferred angioplasty approach was the 20%
risk of recurrent ischemic events early in the hospital course.
In this trial. patients were monitored closely for signs of
ischemia. When chest discomfort and clear-cut ECG changes
occurred. cardiac catheterization was performed immedi-
ately. Emergency coronary angioplasty and. if necessary.
bypass surgery were used to treat recurrent ischemia in all
of these patients. Thus, the timing of angioplasty cannot
always be deferred. and our results suggesl thaI careful
surveillance of patients after thrombolytic therapy is essen-
tial ( 17). Moreover, transfer of the patient to a specialized
center to permit availability of emergency angioplasty may
be important to prevent infarct vessel reclosure and attendant
ventricular dysfunction. In contrast, patients randomized to
immediate angioplasty had a significantly lower risk of re-
current ischemic events.
Recurrent Ischemic Events
As mentioned previously. 18% of patients randomized
to rt-PA alone for I week developed recurrent ischemia
prompting emergency catheterization and either coronary
angioplasty or bypass surgery. Figure 2 shows the timing
of recurrent ischemic events for patients with a patent infarct
vessel and a high grade residual stenosis who were random-
ized to deferred angioplasty. Of the clinically overt events
of defin ite ischemic pain unrelieved by nitrate therapy. ac-
companied by ECG changes. two patterns were distin-
guished by emergency coronary angiography. The first,
characterized by frank coronary occlusion. occurred within
24 hours of thrombolytic treatment in all six patients with
manifest ischemia. The second type of recurrent ischemia,
with virtually the same clinical signs, was correlated with
a high grade residual stenosis hut preserved flow. Many of
these events also took place within 24 hours.
Thus. we conclude that in patients with successful throm-
bolysis and a high grade residual stenosis of the infarct
vessel, there is a clustering of recurrent ischemic events in
the first 24 hours. After this time interval in our relatively
small but well characterized study group. recurrent ischemic
events were less frequent and all episodes of reocclusinn
Table 5. Relation Between Left Ventricular Function and Time to Therapy
Time From Acute EF 7 Day Er
Chest Pain
to rt-PA (h) n Mean -+- SO Median Mean ~ SO" Mediuni
o to < 2 40 0.55 c+. n. 11 0.55 0.56 ± 0. 11 0.511
2 to <3 62 0.53 + 0.10 0.55 0.53 ± 0. 11 0.54
3 to < 4 49 0.51 c+. 0. 10 0.52 0.54 ± 0. 11 n.s)
;:0, 4 25 0.53 -'- o.io 0.55 0.55 ± n.os 0.55
For 0 to 2 hours versus > 2 hours. 7 day ejection fraction: "p = 0. 12. 1 lest; tp = O.OR. Wilcoxon test.
Abbreviations as In Tables I and 3.
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were "silent," that is, without accompanying clear-cut chest
discomfort or ECG changes, or both.
70
Figure 3. A, Results of global left ventricular (LV) function as-
sessed by ejection fraction (EF) for the 24 TAMI patients who
underwent emergency coronary artery bypass surgery. B, Results
of infarct zone regional wall motion study for this patient group.
Wall motion is expressed in units of standard deviation/chord
(SD/CHORD).
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Timing of rt-PA Therapy
The impact of early initiation of fibrinolytic therapy is
shown in Table 5 for the randomized patients. For patients
treated within 2 hours after symptom onset, the left ven-
tricular ejection fraction at 90 minutes of the rt-PA therapy
was similar to that in patients who received rt-PA at later
intervals. However, at I week, the median ejection fraction
was slightly higherin patients who were treated within 2hours
(p = 0.08, Wilcoxon test) compared with those treated later.
A comprehensive analysis of ventricular function from the
TAMI trial will be the subject of a future report.
Emergency Surgical Revascularization
Mortality. A subset of 24 patients (6.2%) in the trial
were transferred directly from the cardiac catheterization
laboratory for emergency coronary bypass graft surgery.
The indication for surgery was left main coronary or equiv-
alent stenosis (left main equivalent was defined as 275%
stenosis of the left anterior descending and circumflex ves-
sels) in 8 patients, severe multi vessel disease not amenable
to angioplasty in 4 patients and failure of angioplasty in 12
patients. In this group, there were no intraoperative deaths
and three subsequent in-hospital deaths (12.5%). This low
mortality rate occurred despite a preoperative diagnosis of
cardiogenic shock (systolic blood pressure <85 mm Hg,
requiring vasopressors) in eight patients (33%). Although
still receiving a prolonged infusion of rt-PA at the time of
induction of anesthesia, only 4 of the 24 patients in this
group had significant postoperative hemorrhage, with 3 pa-
tients requiring mediastinal exploration.
Left ventricular function. In the emergency coronary
bypass surgical group, there was substantial improvement
in global and infarct zone regional ventricular function from
the 90 minute to 1 week follow-up studies (Fig. 3). The
extent of recovery of function in the emergency surgery
group exceeded the functional recovery of the randomized
patients who underwent emergency coronary angioplasty.
The explanation for this finding may lie in more complete
revascularization, myocardial protective effects of cardio-
plegia or cardiopulmonary bypass or a heightened cate-
cholamine state. Alternatively, the lower baseline ejection
fraction of this group left greater room for measurable func-
tional recovery.
Failure of rt-PA Therapy
Of 96 patients whose coronary lesion failed to reperfuse
after 90 minutes of intravenous rt-PA therapy, coronary
angioplasty was attempted in 86 (90%), Compared with
patients with successful recanalization (Table 6), the pa-
tients with unsuccessful rt-PA therapy had a worse prognosis
including: 1) a lower primary angioplasty success rate; 2)
a higher intraprocedural complication rate; and 3) a higher
I week reocclusion rate. Unlike patients with successful
recanalization, the group without rcperfusion after rt-PA had
no improvement in infarct zone regional wall motion or
potentiation of global function. Of the 10 patients who died
in this group (mortality rate 10.4%), 5 had developed car-
JACC Vol. 10. No.5
November 1987:65B- 74B
Table 6. Profile of 96 Patients in Whom rt-PA Therapy Failed
rt-PA Therapy
TOPOL ET AL.
THRQ\,lBOLYSIS AND At\GIOPLASTY
718
Emergency angioplasty attempted
(no.)
Angioplasty success (%)
lntralab complications (%)*
Ventricular fibrillation
Severe sinus bradycardia
Abrupt reclosure
Hypotension
Reocclusion (% over week)
Mortality (in-hospital)
*Refers to cardiac catheterization laboratory.
Unsuccessful
(n = 96)
9
19
13
34
29
lOA
Successful
(n = 288)
99
92
6
8
20
10
5.2
p Value
0. 13
0.05
0.00 1
0. 15
0.02
0 .0009
0.05
diogenic shock and one had severe. refractory arrhythmias
before attempted angioplasty. These data confirm that fail-
ure to reperfuse with intravenous thrombolytic therapy is
associated with a poor prognosis and suggest that new treat-
ment strategies are needed.
Minimal Lesion Syndrome
An insignificant «50%) infarct vessel residual stenosis
was noted 90 minutes after rt-PA therapy in 24 (6%) of the
386 TAMI patients (Table 7). This group has a characteristic
profile that includes younger age, female gender and heavy
cigarette smoking. The mechanism of acute coronary oc-
clusion in this subset is likely to be different, with a pre-
dominant component of thrombus rather than atherosclerotic
plaque. All such patients did, however, have angiographic
evidence of at least minimal intimal irregularities, such that
a nidus for coronary artery spasm or in situ thrombosis, or
both, was present. We have empirically treated these pa-
tients with calcium channel blocking agents. nitrates and
aspirin. Their long-term prognosis is not benign. because
one of the five out-of-hospital deaths occurred in a patient
with the " minimal lesion syndrome." Longer follow-up of
these patients will be important to determine whether they
are at risk of future events.
Clinically Detectable Reperfusion
During the TAMI trial , we prospectively studied the value
of bedside clinical criteria for predicting infarct vessel re-
canalization status after intravenous rt-PA. Table 8 sum-
marizes the ability of each clinical criterion to predict a
patent infarct vessel as determined by simultaneous clinical,
ECG and angiographic assessment 90 minutes after rt-PA
infusion.
The best single predictor of recanalization (96% prob -
ability) at 90 minutes was complete resolution of ST segment
elevation. but this occurred in only 6% of TAM] patients.
Complete relief of chest pain was also a fairly good (84%
probability) predictor of reperfusion. Arrhythmias detected
clinically were not associated with reperfusion. The majority
of patients had no clinical noninvasive signs that could ac-
curately predict reperfusion , Even patients who had no clin-
ical criteria for reperfusion present had a 55% frequency of
a patent infarct vessel. From these data we conclude that,
in most patients. reliable diagnosis of infarct vessel patency
cannot be made using readily available bedside criteria.
Maintenance of Infarct Vessel Patency
The results of the TAMI trial can be understood only in
the context of an aggressive strategy to maintain perfusion
of the infarct-related myocardium. At all centers in the trial,
monitoring for recurrent ischemia was continued throughout
the hospitalization. Repeat angiography was used liberally
to assess the meaning of symptoms or signs of recurrent
ischemia. When clinically important ischemia was present,
coronary angioplasty or bypass surgery was used to establish
or maintain perfusion (Table I). A more passive approach
Table 7. Minimal Coronary Lesion Syndrome (24 patients)
Residual Stenosis After rt-PA Therapy
::0;50% >50'k p Value
No. of patients 24 362
Age (yr) 47.8 ± 10 56 ::: 10 0. 0001
Sex (%F) 38 20 0.04
Cigarette smoker (%) 83 66 0.08
F = female.
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Figure 4. Flow chart for triage recommendations or emergency
angiography and coronary angioplasty in patients with acute myo-
cardial infarction (MI). Anglo = coronary angioplasty; ETT =
exercise treadmill testing: other abbreviations as in Figures 1
and 2.
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tion (TIMI) Study Group and the European Cooperative
Study Group will help to define the role and need for emer-
gency catheterization.
Advantages. Several observations based on the current
study. however, provide some perspective on the merits and
disadvantages of emergency angiography. The emergency
angiogramprecisely definedthecoronary anatomy, allowing
identification of high risk coronary subsets and definitive
assessment of the infarct vessel patency status. Because
failure of thrombolysis can be diagnosed accurately. coro-
nary angioplasty can be used to restore infarct vessel pat-
ency.
Disadvantages. Emergency cardiac catheterization also
has disadvantages, including the potentiation of local peri-
access bleeding, which occurred in nearly half of TAMI
patients and led to a transfusion requirement of 2:2 units of
packed cells in 18% not related to bypass surgery. The
expense, 24 hour personnel requirement and need for rapid
interhospital transport are the other negative aspects of emer-
gencyangiography.
Clinical role. The coupling of two important results
from the TAMI trial allow speculation on the role of emer-
gency cardiac catheterization. First. the lack of need for
emergency angioplasty for patients with successful throm-
bolysis was demonstrated. Second, the patients with un-
successful thrombolytic therapy who underwent "salvage"
angioplasty were plagued with a high rcocclusion rate and
a higher mortality than patients with successful thrombol-
ysis. Together, these results suggest that when a regimen
Proportion of ProbabiIity of
Descriptor Patients Reperfusion
ST segment
Unchanged 0.56 0.63
Improved 0.38 0.84
Resolved 0.06 0.96
Chest pain
Unchanged 1.20 0.60
Improved 0.51 0.71
Resolved 0.29 0.84
Arrhythmia
None 0.64 o.n
VT > tOO beats/min 0.06 0.67
VT < lOO beats/min 0.07 0.75
VF O.Og 0.77
Y AV block 0.03 0.64
3c AV block 0.05 0.74
Severe sinus bradycardia 0.16 0.73
during the hospitalization may have led to a higher failure
rate in the patients randomized to delayed angioplasty. The
low follow-up mortality so far in the trial lends credence to
the concept that persistent perfusion of the infarct zone may
alter prognosis, even in the absence of dramatic improve-
ment in left ventricular function (18).
AV = atrioventricular; VF = ventricular fibrillation; VT = ventricular
tachycardia.
Table 8. Clinical Signs of Reperfusion
Regionalization of Care
In the trial, nearly half (4S%) of the patients were trans-
ferred by helicopter from a satellite community hospital to
the clinical site. Of the 386 patients studied in TAMI. only
37% presented directly to one of the four clinical sites. No
untoward effects occurred during transport, save for tran-
sient hypotension and benign or transient arrhythmias. These
results confirm the safety of interhospital transport of pa-
tients with acute myocardial infarction receiving throm-
bolytic therapy. The TAMI results also suggest the impor-
tance of a regional center with coronary angioplasty and
bypass s.rrgery availability. Even when emergency angi-
ogruphy or angioplasty was not performed. nearly 20% of
patients with a patent vessel developed recurrent ischemia
that could be treated with urgent coronary angioplasty. Ad-
ditionally, more than 20% of the patientsenrolled underwent
surgical rcvascularization before hospital discharge (Ta-
ble 2),
Role of Emergency Cardiac Catheterization
This trial was not intended to test the need for emergency
coronary angiography, owing to the need to define the anat-
omy before randomization. In contrast to our study design,
two ongoing clinical trials are randomizing patients to have
emergency or elective catheterization. The results of these
trials performed by the Thrombolysis in Myocardial lnfarc-
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with a higher initial efficacy and lower reocclusion rate can
bedeveloped. emergency angiography may not be necessary
to achieve optimal clinical benefit for many patients after
intravenous thrombolytic therapy. However. at the current
time. there remains at least a 25% failure rate with intra-
venous thrombolysis. We recommend the use of emergency
coronary angioplasty to provide the diagnosis and set up the
potential for immediate PTCA when thrombolysis has failed .
Newer pharmacologic approaches for this particular patient
subset are likely to yield better results than those obtained
in the TAMI trial in terms of sustained patency. preservation
of ventricular function and long-term prognosis.
Future Directions
"Salvage" angioplasty. From the TAMI trial we learned
that emergency coronary angioplasty was not required after
successful thrombolysis with intravenous rt-PA. Rather than
coronary angiopJasty, the key determinant of in-hospital
clinical course in the TAMI trial and long-term prognosis
in other reperfusion studies appears to be infarct vessel
patency (18-20). However. approximately 25% of patients
will fail I1-PA therapy and might benefit from angioplasty-
induced reperfusion. We have termed this use of angioplasty
..salvage" because it is a method of achieving recanalization
in the setting of failed lytic therapy. Left ventricular function
was not improved by "salvage" angioplasty but there was
a very low 6 month out-of-hospital mortality in the group
of 85 patients (one death, noncardiac) who underwent im-
mediate angioplasty after unsuccessful rt-PA therapy. Fol-
low-up of patients without angioplasty after failure of throm-
bolytic therapy has demonstrated a high out-of-hospital
mortality (18).
Mechanism of thrombolysis failure. The mechanism
by which thrombolysis fails is likely to be multifactorial.
In some patients, the coronary intimal plaque may have
undergone frank rupture or a subintimal hematoma may be
present (21 .22). Others may have a hypercoagulable ten-
dency or an intrinsic fibrinolytic defect (23). Resistance to
lysis despite the presence of coronary thrombus is suggested
by two observations. First. in patients who have unsuc-
cessful thrombolytic therapy and undergo mechanical re-
perfusion. angiographic filling defects are frequently ap-
parent, suggestive of intraluminal thrombus. Second, in the
TAMI trial, the infarct vessel patency rate of 75% was
determined 90 minutes after thrombolytic therapy. Recent
studies with rt-PA suggest that significantly higher rates of
recanalization, approaching 85%, may be achieved by ex-
tending the time of angiographic evaluation to 2 hours, or
18 to 48 hours after therapy (24.25). The reasons for failure
of these clots to lyse at an earlier point after lytic therapy
or at any time remain a topic of investigation.
Recently, the concept of in vivo fibrino lytic synergism
has been introduced (26-28) , By administering a combi-
nation of two thrombolytic agents. it may be possible to
significantly increase the rate and extent of infarct vessel
recanalization. Alternatively. hybrids or mutants of recom-
binant fibrin -selective agents may offer the potential for
heightened thrombolytic effi cacy (29). Although our pri-
mary objective should remain to achieve the highest pro-
portion of patients with infarct vessel patency. this goal may
not be possible or may be achieved only with undue bleeding
complications.
Aggressive approach for high risk patients versus low
risk patients. In the meantime, a practical approach to
treatment can be extrapolated from the TAMI trial results.
The aggressive approach of emergency cardiac catheteriza-
tion, with coronary angioplasty or bypass surgery as needed.
may be especially appropriate for the high risk patients.
This group includes patients with cardiogenic shock. ex-
tensive anterior infarction or prior remote (territory) trans-
mural infarction. Urgent coronary revascularization in these
patients may be a major factor accounting for the very low
out-of-hospital patient mortality in the TAMI trial. On the
other hand. patients with a low risk infarction may be well
suited for thrombolytic therapy alone. with predischarge
exercise testing or a "screening" coronary angiogram. This
triage scheme is represented in Figure 4. Certainly. new
noninvasive methods to accurately detect reperfusion would
be quite helpful and permit even less urgent coronary an-
giography (30).
Reperfusion injury. The extent and importance of re-
perfusion injury in humans remain unclear (31.32). With
the relatively high left ventricular ejection fraction noted in
the TAMI randomized patients. it may be increasingly dif-
ficult to document an additive protective effect for such
agents as beta-blockers or free radical oxygen scavengers.
This area of clinical investigation, however, has marked
potential for even further limitation of infarct size.
Conclusions. Since early trials of myocardial reperfu-
sion (33). we have made considerable progress with the
integration of intravenous clot-selective agents and me-
chanical recanalization. The combination of these myo-
cardial reperfusion strategies is currently the focus of several
large scale randomized clinical trials. Adjunctive pharma-
cologic therapy with agents to further increase thrombolytic
efficacy or reduce myonecrosis will be the subject of future
TAMI Study Group investigations.
w~ thank Hetty Plunkett for preparation of the manuscript.
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